Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.51 |
| ▸ | NQO1 | P15559 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.43 |
| ▸ | ABCC1 | P33527 | 5/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.42 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.42 |
| ▸ | ALDH1B1 | P30837 | 1/20 | 0.42 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6734922 | 0.88 | ACHE (0.52) | ACHENQO1MEN1KMT2AKDM4E | |
| SCHEMBL8807147 | 0.86 | ACHE (0.53) | ACHENQO1MEN1KMT2AKDM4E | |
| SCHEMBL8807846 | 0.82 | ACHE (0.48) | ACHENQO1MEN1KMT2AKDM4E | |
| SCHEMBL8745793 | 0.78 | NQO1 (0.56) | NQO1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL9080519 | 0.77 | NQO1 (0.58) | ACHENQO1MEN1KMT2AKDM4E | |
| SCHEMBL8806039 | 0.77 | ALDH1A1 (0.57) | MEN1KMT2AKDM4EMAPTALDH1A2 | |
| SCHEMBL8807713 | 0.76 | ALDH1A1 (0.48) | ACHENQO1KDM4EMAPTALDH1A2 | |
| SCHEMBL16698722 | 0.75 | ALDH1A1 (0.61) | ACHENQO1MEN1KMT2AKDM4E | |
| SCHEMBL11099484 | 0.75 | ACHE (0.66) | ACHEKDM4EMAOB | |
| SCHEMBL8805913 | 0.74 | DRD2 (0.71) | ABCB1ABCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014768-A1 | Chromenone derivatives and their use for treating diseases in conjunction with 5-hta1receptors and/or dopamine d2 receptors | MERCK PATENT GMBH (DE) | 2004-01-22 | — | — | US | disclosed |
| EP-1311503-A1 | CHROMENONE DERIVATIVES AND THEIR USE FOR TREATING DISEASES IN CONJUNCTION WITH 5-HTA1 RECEPTORS AND/OR DOPAMINE D2 RECEPTORS | MERCK PATENT GmbH (DE) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002016354-A1 | CHROMENONE DERIVATIVES AND THEIR USE FOR TREATING DISEASES IN CONJUNCTION WITH 5-HTA1 RECEPTORS AND/OR DOPAMINE D2 RECEPTORS | MERCK PATENT GMBH (DE) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014768-A1 | Chromenone derivatives and their use for treating diseases in conjunction with 5-hta1receptors and/or dopamine d2 receptors | HTR1A, HTR1D, HTR1E | ACHE 1432/4885NQO1 1825/4885MEN1 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.